## SENTARA COMMUNITY PLAN (MEDICAID)

## MEDICAL PRIOR AUTHORIZATION/STEP-EDIT REQUEST\*

<u>Directions:</u> The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; <u>fax to 1-844-305-2331</u>. No additional phone calls will be necessary if all information (<u>including phone and fax #s</u>) on this form is correct. <u>If information provided is not complete</u>, correct, or legible, authorization can be delayed.

## **Non-Preferred Parenteral Iron Products**

PREFERRED

**<u>Drug Requested</u>**: (select **ONE** of drugs below) (**Medical**)

|  |                           | No prior authoriza                           | tion required      |                      |                                 |
|--|---------------------------|--|--------------------|----------------------|---------------------------------|
| □ Feraheme®  (ferumoxytol) (For  ESRD on Dialysis)   | fer                       | errlecit® (sodium ric gluconate mplex) J2916 |                    |                      | □ Venofer® (iron sucrose) J1756 |
| Q0139  |                           | • /  |                    |                      |                                 |
|  |                           | NON-PREF                                     |                    |                      |                                 |
| Prior authorization required as noted below  □ Feraheme® (ferumoxytol) □ Injectafer® (ferric □ Monoferric® (ferric |                           |  |                    |                      |                                 |
| (Non-ESRD) Q0138   |                           | □ Injectafer® (ferric carboxymaltose) J1439  |                    | derisomaltose) J1437 |                                 |
| MEMBER & PRESCR  | IBER I                    | INFORMATIO                                   | N: Authorization   | may be de            | elayed if incomplete.           |
| Member Name:   |                           |  |                    |                      |                                 |
| Member Sentara #:  | Date of Birth:            |  |                    |                      |                                 |
| Prescriber Name:   |                           |  |                    |                      |                                 |
| Prescriber Signature:  | escriber Signature: Date: |  |                    |                      |                                 |
| Office Contact Name:   |                           |  |                    |                      |                                 |
| Phone Number:  | one Number: Fax Number:   |  |                    |                      |                                 |
| DEA OR NPI #:  |                           |  |                    |                      |                                 |
| DRUG INFORMATIO  | N: Auth                   | norization may be d                          | elayed if incomple | te.                  |                                 |
| Drug Form/Strength:  |                           |  |                    |                      |                                 |
| Dosing Schedule: Length of Therapy:  |                           |  |                    |                      |                                 |
| Diagnosis:   | ICD Code, if applicable:  |  |                    |                      |                                 |
| Weight:  | Date:                     |  |                    |                      |                                 |

(Continued on next page)

## PA Non-Preferred Parenteral Iron Products (Medical)(Medicaid)

(Continued from previous page

| each | <b>NICAL CRITERIA:</b> Check below all that apply. All criteria must be met for approval. To support line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided quest may be denied. |
|------|---|
| Len  | gth of Authorization: 2 months  |
| Dia  | gnosis – Select <u>ONE</u> of the following diagnoses below:  |
|      | Diagnosis: Iron-deficiency anemia   |
|      | Provider has submitted the following labs collected within the last 30 days:  |
|      | ☐ Serum ferritin (iron) AND total iron binding capacity (TIBC)  |
|      | □ Transferrin saturation (TSAT%) *Note: TSAT% = (Serum iron/TIBC) x 100%  |
|      | Lab documentation show member's TSAT < 20%  |
|      | Provider has submitted documentation to confirm member has tried and failed <b>ONE</b> of the following preferred parenteral iron preparations  |
|      | ☐ Feraheme® (ferumoxide) for ESRD on Dialysis   |
|      | ☐ Ferrlecit® (sodium ferric gluconate complex)  |
|      | □ INFeD <sup>®</sup> (iron dextran)   |
|      | □ Venofer <sup>®</sup> (iron sucrose)   |
|      | Diagnosis: Moderate-to-severe restless leg syndrome (RLS)   |
|      | Member is 18 years of age and older   |
|      | Provider has submitted the following labs collected within the last 30 days:  |
|      | ☐ Serum ferritin (iron) <u>AND</u> total iron binding capacity (TIBC)   |
|      | Transferrin saturation (TSAT%) *Note: TSAT% = (Serum iron/TIBC) x 100%  |
|      | Lab documentation shows member's TSAT <20% after trial of an oral iron supplement   |
|      | Member has tried and had an unsatisfactory response, intolerance or contraindication to oral iron administration  |
|      | Provider has submitted documentation to confirm member has tried and failed <b>ONE</b> of the following preferred parenteral iron preparations  |
|      | ☐ Feraheme® (ferumoxytol) for ESRD on Dialysis  |
|      | ☐ Ferrlecit® (sodium ferric gluconate complex)  |
|      | □ INFeD® (iron dextran)   |
|      | □ Venofer <sup>®</sup> (iron sucrose)   |

(Continued on next page)

| o I | Diagnosis: Management of cancer and chemotherapy-induced anemia  |
|-----|--|
|     | Provider has submitted the following labs collected within the last 30 days:   |
|     | ☐ Serum ferritin (iron) <u>AND</u> total iron binding capacity (TIBC)  |
|     | □ Transferrin saturation (TSAT%) *Note: TSAT% = (Serum iron/TIBC) x 100%   |
|     | Provider has submitted documentation to confirm member has tried and failed <b>ONE</b> of the following preferred parenteral iron preparations |
|     | ☐ Feraheme® (ferumoxytol) for ESRD on Dialysis   |
|     | ☐ Ferrlecit® (sodium ferric gluconate complex)   |
|     | ☐ INFeD® (iron dextran)  |
|     | ☐ Venofer® (iron sucrose)  |
|     | Member has functional iron deficiency and must meet <b>ONE</b> of the following:   |
|     | ☐ Member has a TSAT < 50% with the goal of avoiding allogenic transfusion  |
|     | ☐ Member has a TSAT < 50% and requested medication will be used in combination with erythropoise stimulating agents (ESAs)                     |
| Med | dication being provided by (check applicable box(es) below):   |
|     | Location/site of drug administration:  |
|     | NPI or DEA # of administering location:  |
|     | OR   |
|     | <del></del>  |
| _   | Specialty Pharmacy – Proprium Rx   |
|     |  |

For urgent reviews: Practitioner should call Sentara Health Pre-Authorization Department if they believe a standard review would subject the member to adverse health consequences. Sentara Health's definition of urgent is a lack of treatment that could seriously jeopardize the life or health of the member or the member's ability to regain maximum function.

\*\*Use of samples to initiate therapy does not meet step edit/ preauthorization criteria. \*\*

\*Previous therapies will be verified through pharmacy paid claims or submitted chart notes. \*